Atherothrombotic events and clopidogrel therapy [2]

CMAJ. Canadian Medical Association Journal

Volumn 176, Issue 3, 2007, Pages 349-

  McLachlan, Craig S ^a   Tay, Stacey K H ^a   Almsherqi, Zakaria ^a   Chia, Shu Hui ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; CYTOCHROME P450 3A5; THIENOPYRIDINE; UNCLASSIFIED DRUG; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; ENZYME INHIBITOR; TICLOPIDINE;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG ELUTING STENT; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; RISK ASSESSMENT; STENT; THROMBOCYTE AGGREGATION; THROMBOSIS; AGED; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INTERACTION; FAT EMBOLISM; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; NOTE; RISK FACTOR;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EMBOLISM, CHOLESTEROL; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; THROMBOSIS; TICLOPIDINE;

EID: 33846968847     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.1060153     Document Type: Letter

References (5)

1. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22.
2. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, et al; TRUE (Taxus in Real-Life Usage Evaluation) Study Investigators. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) study. Int J Cardiol 2006;108:406-7.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006;55:780-4.
4. Jimenez-Quevedo P, Angiolillo DJ, Bernardo E, et al. Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance? Catheter Cardiovasc Interv 2004;62:39-42.
5. Almsherqi ZA, McLachlan CS, Sharef SM. More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized cross-over trial [letter]. J Thromb Haemost 2006;4:1-2.